Evitria

Evitria is a privately held, revenue-generating service provider focused exclusively on recombinant antibody expression in CHO cells. The company leverages deep expertise, a proprietary technology toolbox, and a rapid execution model (project initiation within 24 hours) to serve biopharma clients globally. Its business is built on providing flexible, high-throughput production services for complex antibody formats, acting as a critical outsourced partner for therapeutic developers rather than developing its own drug pipeline. Headquartered near Zurich, Switzerland, Evitria has established a global presence supporting innovators in the antibody therapeutics space.

Specialized recombinant antibody expression services in CHO cells, utilizing licensed technologies for afucosylation (GlymaxX®), Fc-silencing (bYlok®), and high-throughput production.

Evitria competes in the biologics CRO/CDMO space against giants like Lonza, Samsung Biologics, and WuXi Biologics, as well as specialized peers like Absolute Antibody, Bio-Techne's Protein Sciences segment, and numerous regional players. Its differentiation is its exclusive focus on antibody expression, rapid turnaround, and access to specific engineering technologies.